ATE427125T1 - Tc und re markierte radioaktive glycosylierte octreotid-derivate - Google Patents
Tc und re markierte radioaktive glycosylierte octreotid-derivateInfo
- Publication number
- ATE427125T1 ATE427125T1 AT02723932T AT02723932T ATE427125T1 AT E427125 T1 ATE427125 T1 AT E427125T1 AT 02723932 T AT02723932 T AT 02723932T AT 02723932 T AT02723932 T AT 02723932T AT E427125 T1 ATE427125 T1 AT E427125T1
- Authority
- AT
- Austria
- Prior art keywords
- ligands
- sst
- improved
- chelator
- radioisotope
- Prior art date
Links
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical class C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 title 1
- 230000002285 radioactive effect Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 6
- 239000002738 chelating agent Substances 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 125000000837 carbohydrate group Chemical group 0.000 abstract 1
- 238000010668 complexation reaction Methods 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 238000009206 nuclear medicine Methods 0.000 abstract 1
- 239000000816 peptidomimetic Chemical group 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01201466 | 2001-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE427125T1 true ATE427125T1 (de) | 2009-04-15 |
Family
ID=8180193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02723932T ATE427125T1 (de) | 2001-04-23 | 2002-04-23 | Tc und re markierte radioaktive glycosylierte octreotid-derivate |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7589061B2 (https=) |
| EP (1) | EP1381396B1 (https=) |
| JP (3) | JP5398945B2 (https=) |
| AT (1) | ATE427125T1 (https=) |
| AU (1) | AU2002254691B8 (https=) |
| BR (1) | BR0209074A (https=) |
| CA (1) | CA2443273C (https=) |
| CZ (1) | CZ20032872A3 (https=) |
| DE (1) | DE60231801D1 (https=) |
| HU (1) | HU228811B1 (https=) |
| WO (1) | WO2002085418A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL157086A0 (en) * | 2003-07-24 | 2004-02-08 | Guy Patchornik | Multivalent ligand complexes |
| US7956165B2 (en) | 2003-07-24 | 2011-06-07 | Affisink Biotechnology Ltd. | Compositions and methods for purifying and crystallizing molecules of interest |
| CN102253174A (zh) * | 2011-04-27 | 2011-11-23 | 江苏省原子医学研究所 | 一种受体显像剂标记的化学动力学研究的方法 |
| AU2012302636B2 (en) * | 2011-09-04 | 2016-09-15 | Glytech, Inc. | Glycosylated polypeptide and drug composition containing said polypeptide |
| BR112014004936A2 (pt) * | 2011-09-04 | 2017-04-04 | Glytech Inc | polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeo |
| PL3152226T3 (pl) * | 2014-06-06 | 2019-10-31 | Univ Muenchen Tech | Modyfikowane cyklopentapeptydy i ich zastosowania |
| HRP20231458T1 (hr) | 2017-01-12 | 2024-05-10 | Radiomedix Inc. | Liječenje stanica raka koje prekomjerno eksprimiraju receptore za somatostatin primjenom derivata oktreotida keliranih sa radioizotopima |
| CN113747927B (zh) * | 2019-02-14 | 2024-10-18 | 德国癌症研究中心 | 包含淀粉酶可切割接头的前列腺特异性膜抗原(psma)配体 |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL194729C (nl) * | 1986-10-13 | 2003-01-07 | Novartis Ag | Werkwijze voor de bereiding van peptidealcoholen via vaste fase. |
| JP2544159B2 (ja) | 1987-10-07 | 1996-10-16 | ハウス食品株式会社 | 連続蒸煮装置 |
| MY106120A (en) | 1988-12-05 | 1995-03-31 | Novartis Ag | Peptide derivatives. |
| US5590656A (en) * | 1992-09-15 | 1997-01-07 | The Ohio State University Research Foundation | Application of peptide/cell receptor kinetics utilizing radiolabeled somatostatin congeners in the in situ, in vivo detection and differentiation of neoplastic tissue |
| US5968477A (en) | 1994-01-24 | 1999-10-19 | Neorx Corporation | Radiolabeled annexin conjugates with hexose and a chelator |
| EP0799050B1 (en) | 1994-12-07 | 2004-08-11 | Neorx Corporation | Radiolabeled annexin-galactose cluster conjugates |
| JPH10512852A (ja) | 1994-12-07 | 1998-12-08 | ネオルクス コーポレイション | 放射性標識化アネキシン−ガラクトースクラスター複合体 |
| US5753206A (en) * | 1995-06-07 | 1998-05-19 | Immunomedics, Inc. | Radiometal-binding analogues of luteinizing hormone releasing hormone |
| AU1821397A (en) | 1995-12-21 | 1997-11-07 | Scripps Research Institute, The | Targeted therapeutic or diagnostic agents and methods of making and using same |
| DE19654764A1 (de) | 1996-12-30 | 1998-07-02 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung eines Peptidgemisches |
| EP1068224B1 (en) | 1998-03-31 | 2005-05-11 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
| DE19910419A1 (de) | 1999-03-10 | 2000-09-21 | Aventis Pharma Gmbh | Zielzellspezifische, multivalente Proteine (MVP) |
-
2002
- 2002-04-23 DE DE60231801T patent/DE60231801D1/de not_active Expired - Lifetime
- 2002-04-23 JP JP2002582991A patent/JP5398945B2/ja not_active Expired - Fee Related
- 2002-04-23 HU HU0303987A patent/HU228811B1/hu not_active IP Right Cessation
- 2002-04-23 AU AU2002254691A patent/AU2002254691B8/en not_active Ceased
- 2002-04-23 EP EP02723932A patent/EP1381396B1/en not_active Expired - Lifetime
- 2002-04-23 BR BR0209074-0A patent/BR0209074A/pt not_active IP Right Cessation
- 2002-04-23 CZ CZ20032872A patent/CZ20032872A3/cs unknown
- 2002-04-23 CA CA2443273A patent/CA2443273C/en not_active Expired - Fee Related
- 2002-04-23 US US10/475,696 patent/US7589061B2/en not_active Expired - Fee Related
- 2002-04-23 AT AT02723932T patent/ATE427125T1/de not_active IP Right Cessation
- 2002-04-23 WO PCT/US2002/012565 patent/WO2002085418A2/en not_active Ceased
-
2009
- 2009-09-10 US US12/556,698 patent/US8575100B2/en not_active Expired - Fee Related
- 2009-09-30 JP JP2009228998A patent/JP2010001313A/ja not_active Withdrawn
-
2013
- 2013-02-08 JP JP2013023001A patent/JP2013100349A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0303987A3 (en) | 2010-03-29 |
| WO2002085418A3 (en) | 2003-09-12 |
| US20090324497A1 (en) | 2009-12-31 |
| AU2002254691B8 (en) | 2008-02-14 |
| DE60231801D1 (de) | 2009-05-14 |
| JP2005514321A (ja) | 2005-05-19 |
| BR0209074A (pt) | 2004-08-10 |
| CZ20032872A3 (cs) | 2005-01-12 |
| EP1381396A2 (en) | 2004-01-21 |
| US7589061B2 (en) | 2009-09-15 |
| US20060165593A1 (en) | 2006-07-27 |
| JP5398945B2 (ja) | 2014-01-29 |
| CA2443273A1 (en) | 2002-10-31 |
| EP1381396B1 (en) | 2009-04-01 |
| US8575100B2 (en) | 2013-11-05 |
| HU228811B1 (hu) | 2013-05-28 |
| JP2010001313A (ja) | 2010-01-07 |
| CA2443273C (en) | 2011-09-27 |
| HUP0303987A2 (hu) | 2004-03-01 |
| AU2002254691B2 (en) | 2007-06-14 |
| JP2013100349A (ja) | 2013-05-23 |
| WO2002085418A2 (en) | 2002-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bullok et al. | Characterization of novel histidine-tagged Tat-peptide complexes dual-labeled with 99mTc-tricarbonyl and fluorescein for scintigraphy and fluorescence microscopy | |
| Decristoforo et al. | Preparation, 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3] octreotide | |
| Hosseinimehr et al. | Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design | |
| EP0994724A4 (en) | METHODS AND COMPOSITIONS TO PREVENT THE REPRODUCTION OF HIV-1 | |
| Tran et al. | In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules | |
| SI1105409T1 (sl) | Zascita endogenih peptidov pred peptidazno ucinkovitostjo s konjugacijo na krvne komponente | |
| AU8269898A (en) | Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor | |
| DK1180121T3 (da) | Langtidsvirkende insulinotrope peptider | |
| Maes et al. | Novel 99mTc-labeled neurotensin analogues with optimized biodistribution properties | |
| ES2114209T3 (es) | Queladores de radionuclidos de tipo hidrazino que tienen una configuracion n3s. | |
| ATE427125T1 (de) | Tc und re markierte radioaktive glycosylierte octreotid-derivate | |
| Achilefu et al. | Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors | |
| HK189995A (en) | Detectable somatostatin analogues containing a chelating group | |
| WO2003077727A3 (en) | Technetium-dipyridine complexes, and methods of use thereof | |
| CA2219492A1 (en) | Peptide radiopharmaceutical applications | |
| N Eberle et al. | Synthetic peptide drugs for targeting skin cancer: malignant melanoma and melanotic lesions | |
| JPH04506343A (ja) | ターゲッティング薬剤 | |
| Lee et al. | Drug targeting to the brain using avidin-biotin technology in the mouse (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease) | |
| AU2002254691A1 (en) | Tc and Re labeler radioactive glycosylated octreotide derivatives | |
| Miranda-Olvera et al. | Synthesis of oxytocin HYNIC derivatives as potential diagnostic agents for breast cancer | |
| Chavatte et al. | Rhenium (Re) and technetium (Tc)‐99M oxocomplexes of neurotensin (8‐13) | |
| Hoffman | GRP receptor-specific analogues of Bombesin | |
| WO2002048175A3 (en) | Mhc class i associated peptides for prevention and treatment of tuberculosis | |
| FI943306L (fi) | Menetelmä farmaseuttisesti käytt¦kelpoisen radionuklidin kanssa kompleksoidun ligandin valmistamiseksi | |
| JPH07206895A (ja) | 炎症親和性ペプチド及び該ペプチドを含有してなる放射性診断剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |